VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.

Soleno Therapeutics Inc (SLNO) reports a strong initial market response to Vykat XR despite a significant net loss and high operational expenses in Q1 2025.

Investing.com -- Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares gained 2.6% after the biopharmaceutical company provided an update on the U.S. launch of its newly approved drug VYKAT XR and reported ...

Soleno Therapeutics, Inc. (SLNO) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors. A solid ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports ...

Amicus Therapeutics FOLD is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...